-+ 0.00%
-+ 0.00%
-+ 0.00%

Faeth Therapeutics wins FDA fast-track status for PIKTOR-paclitaxel in advanced endometrial cancer

PUBT·08/17/2026 11:33:14
Listen to the news
Faeth Therapeutics wins FDA fast-track status for PIKTOR-paclitaxel in advanced endometrial cancer
  • Faeth Therapeutics received FDA Fast Track designation for sapanisertib and serabelisib (PIKTOR) with paclitaxel in biomarker-selected advanced or recurrent endometrial cancer.
  • The designation covers patients with PI3K/AKT/mTOR pathway alterations whose disease progressed following platinum-based chemotherapy and an immune checkpoint inhibitor.
  • The company expects topline data from its Phase 2 Study FTH-PIK-201 in second-line advanced endometrial cancer by year-end 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faeth Therapeutics Inc published the original content used to generate this news brief on August 17, 2026, and is solely responsible for the information contained therein.